New hope drug enters human testing for Tough-to-Treat cancers
NCT ID NCT07217171
Summary
This is the first study in people testing a new drug called EVOLVE104. It aims to find a safe dose and see if it can help control advanced bladder and several types of squamous cell cancers. The study is for patients whose cancer has continued to grow despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
-
SCRI
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Email: •••••@•••••
-
The Winship Cancer Institute Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Email: •••••@•••••
-
Thomas Jefferson University, Sidney Kimmel Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
-
USC/Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact Email: •••••@•••••
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
Contact Email: •••••@•••••
-
Yale University Cancer Center
RECRUITINGNew Haven, Connecticut, 06511, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.